Caris Life Sciences, Inc. (NASDAQ: CAI)

Sector: Healthcare Industry: Biotechnology CIK: 0002019410
P/B 1.98
P/E -2.51
P/S 2.30
Market Cap 949.55 Mn
ROIC (Qtr) 0.00
Div Yield % 0.00
Rev 1y % (Qtr) 113.38
Total Debt (Qtr) 376.46 Mn
Debt/Equity (Qtr) 0.79

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 754.74M provide 4602.07x coverage of short-term debt 164000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 965.23M provides 2.56x coverage of total debt 376.46M, indicating robust asset backing and low credit risk.
  • Tangible assets of 965.23M provide robust 16.97x coverage of other current liabilities 56.87M, indicating strong asset backing.
  • Strong cash position of 754.74M provides 13.27x coverage of other current liabilities 56.87M, indicating excellent liquidity.
  • Cash reserves of 754.74M provide solid 17.20x coverage of other non-current liabilities 43.88M, indicating strong liquidity.

Cons

  • Retained earnings of (2.63B) provide limited buffer against comprehensive income items of 748000, which is -3516.97x, indicating elevated exposure to market risks.
  • Tangible assets of 965.23M provide limited backing for working capital of 768.22M, which is 1.26x, suggesting increased operational risk in market downturns.
  • Other non-current assets of 46.98M provide minimal coverage for long-term debt of 376.30M, which is 0.12x, indicating potential asset-liability mismatch.
  • Current liabilities of 86.03M significantly exceed receivables of 26.70M, which is 3.22x, indicating potential working capital stress.
  • Other current liabilities of 56.87M represent a high 2.13x of receivables 26.70M, suggesting potential short-term liquidity pressure.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 0.00 12.31
EV to Cash from Ops. 0.00 23.25
EV to Debt 0.00 738.44
EV to EBIT 0.00 -9.16
EV to EBITDA 0.00 6.95
EV to Free Cash Flow [EV/FCF] 0.00 21.90
EV to Market Cap 0.00 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 1.98 22.34
Price to Earnings [P/E] -2.51 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 0.00 -27.13
Cash and Equivalents Growth (1y) % 0.00 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % 0.00 -46.93
EBITDA Growth (1y) % 0.00 -1.68
EBIT Growth (1y) % 0.00 -56.45
EBT Growth (1y) % 0.00 -12.70
EPS Growth (1y) % 0.00 -28.31
FCF Growth (1y) % 0.00 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 8.77 3.85
Current Ratio 9.93 7.27
Debt to Equity Ratio 0.79 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22